Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Mutations associated with a 17-gene leukemia stem cell score and its prognostic relevance in the context of the European LeukemiaNet classification for acute myeloid leukemia.

Bill M, Nicolet D, Kohlschmidt J, Walker CJ, Mrózek K, Eisfeld AK, Papaioannou D, Rong-Mullins X, Brannan Z, Kolitz JE, Powell BL, Archer KJ, Dorrance AM, Carroll AJ, Stone RM, Byrd JC, Garzon R, Bloomfield CD; Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology.

Haematologica. 2019 Aug 14. pii: haematol.2019.225003. doi: 10.3324/haematol.2019.225003. [Epub ahead of print]

2.

Correction: Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation.

Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, Croce CM, van Wijnen AJ, Stein JL, Stein GS, Lian JB.

J Biol Chem. 2019 Jun 21;294(25):10018. doi: 10.1074/jbc.AAC119.009552. No abstract available.

3.

Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.

Alméciga-Diaz CJ, Hidalgo OA, Olarte-Avellaneda S, Rodríguez-López A, Guzman E, Garzón R, Pimentel-Vera LN, Puentes-Tellez MA, Rojas-Rodriguez AF, Gorshkov K, Li R, Zheng W.

J Med Chem. 2019 Jul 11;62(13):6175-6189. doi: 10.1021/acs.jmedchem.9b00428. Epub 2019 Jun 25.

PMID:
31188588
4.

Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia.

Papaioannou D, Nicolet D, Ozer HG, Mrózek K, Volinia S, Fadda P, Carroll AJ, Kohlschmidt J, Kolitz JE, Wang ES, Stone RM, Byrd JC, Garzon R, Bloomfield CD.

Mol Cancer Ther. 2019 Aug;18(8):1451-1459. doi: 10.1158/1535-7163.MCT-18-1125. Epub 2019 Jun 4.

PMID:
31164409
5.

Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.

Jeon JY, Zhao Q, Buelow DR, Phelps M, Walker AR, Mims AS, Vasu S, Behbehani G, Blachly J, Blum W, Klisovic RB, Byrd JC, Garzon R, Baker SD, Bhatnagar B.

Invest New Drugs. 2019 May 17. doi: 10.1007/s10637-019-00786-4. [Epub ahead of print]

PMID:
31102119
6.

Evaluation of Starch⁻Protein Interactions as A Function of pH.

Bravo-Núñez Á, Garzón R, Rosell CM, Gómez M.

Foods. 2019 May 7;8(5). pii: E155. doi: 10.3390/foods8050155.

7.

Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells.

Bill M, Papaioannou D, Karunasiri M, Kohlschmidt J, Pepe F, Walker CJ, Walker AE, Brannan Z, Pathmanathan A, Zhang X, Mrózek K, LaRocco A, Volinia S, Bloomfield CD, Garzon R, Dorrance AM.

Leukemia. 2019 Mar 11. doi: 10.1038/s41375-019-0429-5. [Epub ahead of print]

PMID:
30858548
8.

Knockout of both miR-15/16 loci induces acute myeloid leukemia.

Lovat F, Fassan M, Sacchi D, Ranganathan P, Palamarchuk A, Bill M, Karunasiri M, Gasparini P, Nigita G, Distefano R, Veneziano D, Dorrance AM, Garzon R, Croce CM.

Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):13069-13074. doi: 10.1073/pnas.1814980115. Epub 2018 Nov 26.

9.

Toll-Like Receptor Stimulation by MicroRNAs in Acute Graft-vs.-Host Disease.

Zitzer NC, Garzon R, Ranganathan P.

Front Immunol. 2018 Nov 5;9:2561. doi: 10.3389/fimmu.2018.02561. eCollection 2018. Review.

10.

MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function.

Zitzer NC, Snyder K, Meng X, Taylor PA, Efebera YA, Devine SM, Blazar BR, Garzon R, Ranganathan P.

J Immunol. 2018 Jun 15;200(12):4170-4179. doi: 10.4049/jimmunol.1701465. Epub 2018 May 2.

11.

Understanding the effect of emulsifiers on bread aeration during breadmaking.

Garzón R, Hernando I, Llorca E, Rosell CM.

J Sci Food Agric. 2018 Nov;98(14):5494-5502. doi: 10.1002/jsfa.9094. Epub 2018 Jun 9.

PMID:
29691873
12.

Mimicking gluten functionality with β-conglycinin concentrate: Evaluation in gluten free yeast-leavened breads.

Espinosa-Ramírez J, Garzon R, Serna-Saldivar SO, Rosell CM.

Food Res Int. 2018 Apr;106:64-70. doi: 10.1016/j.foodres.2017.12.055. Epub 2017 Dec 20.

PMID:
29579970
13.

A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.

Mims AS, Mishra A, Orwick S, Blachly J, Klisovic RB, Garzon R, Walker AR, Devine SM, Walsh KJ, Vasu S, Whitman S, Marcucci G, Jones D, Heerema NA, Lozanski G, Caligiuri MA, Bloomfield CD, Byrd JC, Piekarz R, Grever MR, Blum W.

Haematologica. 2018 Jun;103(6):982-987. doi: 10.3324/haematol.2017.186890. Epub 2018 Mar 22.

14.

Use of high hydrostatic pressure to inactivate natural contaminating microorganisms and inoculated E. coli O157:H7 on Hermetia illucens larvae.

Kashiri M, Marin C, Garzón R, Rosell CM, Rodrigo D, Martínez A.

PLoS One. 2018 Mar 22;13(3):e0194477. doi: 10.1371/journal.pone.0194477. eCollection 2018.

15.

Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia.

Ngankeu A, Ranganathan P, Havelange V, Nicolet D, Volinia S, Powell BL, Kolitz JE, Uy GL, Stone RM, Kornblau SM, Andreeff M, Croce CM, Bloomfield CD, Garzon R.

Oncotarget. 2017 Dec 12;9(4):4354-4365. doi: 10.18632/oncotarget.23150. eCollection 2018 Jan 12.

16.

Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia.

Di Marcantonio D, Martinez E, Sidoli S, Vadaketh J, Nieborowska-Skorska M, Gupta A, Meadows JM, Ferraro F, Masselli E, Challen GA, Milsom MD, Scholl C, Fröhling S, Balachandran S, Skorski T, Garcia BA, Mirandola P, Gobbi G, Garzon R, Vitale M, Sykes SM.

Clin Cancer Res. 2018 Feb 1;24(3):608-618. doi: 10.1158/1078-0432.CCR-17-2684. Epub 2017 Nov 10.

17.

Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia.

Papaioannou D, Shen C, Nicolet D, McNeil B, Bill M, Karunasiri M, Burke MH, Ozer HG, Yilmaz SA, Zitzer N, Behbehani GK, Oakes CC, Steiner DJ, Marcucci G, Powell BL, Kolitz JE, Carter TH, Wang ES, Mrózek K, Croce CM, Caligiuri MA, Bloomfield CD, Garzon R, Dorrance AM.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4641-E4647. doi: 10.1073/pnas.1703142114. Epub 2017 May 22.

18.

[STAT3 activation by hypoxia in in vitro models of cervix cancer and endothelial cells].

Ortega Ó, Ondo-Méndez A, Garzón R.

Biomedica. 2017 Jan 24;37(1):119-130. doi: 10.7705/biomedica.v37i2.3225. Spanish.

19.

P53 suppresses ribonucleotide reductase via inhibiting mTORC1.

He Z, Hu X, Liu W, Dorrance A, Garzon R, Houghton PJ, Shen C.

Oncotarget. 2017 Jun 20;8(25):41422-41431. doi: 10.18632/oncotarget.17440.

20.

Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells.

Zhou X, Liu W, Hu X, Dorrance A, Garzon R, Houghton PJ, Shen C.

Sci Rep. 2017 May 8;7(1):1535. doi: 10.1038/s41598-017-01729-w.

21.

Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia.

Papaioannou D, Nicolet D, Volinia S, Mrózek K, Yan P, Bundschuh R, Carroll AJ, Kohlschmidt J, Blum W, Powell BL, Uy GL, Kolitz JE, Wang ES, Eisfeld AK, Orwick SJ, Lucas DM, Caligiuri MA, Stone RM, Byrd JC, Garzon R, Bloomfield CD.

Haematologica. 2017 Aug;102(8):1391-1400. doi: 10.3324/haematol.2017.166215. Epub 2017 May 4.

22.

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.

Kuruvilla J, Savona M, Baz R, Mau-Sorensen PM, Gabrail N, Garzon R, Stone R, Wang M, Savoie L, Martin P, Flinn I, Jacoby M, Unger TJ, Saint-Martin JR, Rashal T, Friedlander S, Carlson R, Kauffman M, Shacham S, Gutierrez M.

Blood. 2017 Jun 15;129(24):3175-3183. doi: 10.1182/blood-2016-11-750174. Epub 2017 May 3.

23.

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.

Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, Savoie L, Mau-Sorensen PM, Wagner-Johnston N, Yee K, Unger TJ, Saint-Martin JR, Carlson R, Rashal T, Kashyap T, Klebanov B, Shacham S, Kauffman M, Stone R.

Blood. 2017 Jun 15;129(24):3165-3174. doi: 10.1182/blood-2016-11-750158. Epub 2017 Mar 23.

24.

Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding.

Ranganathan P, Ngankeu A, Zitzer NC, Leoncini P, Yu X, Casadei L, Challagundla K, Reichenbach DK, Garman S, Ruppert AS, Volinia S, Hofstetter J, Efebera YA, Devine SM, Blazar BR, Fabbri M, Garzon R.

J Immunol. 2017 Mar 15;198(6):2500-2512. doi: 10.4049/jimmunol.1601778. Epub 2017 Feb 3.

25.

Oxidative Stress Promotes Doxorubicin-Induced Pgp and BCRP Expression in Colon Cancer Cells Under Hypoxic Conditions.

Pinzón-Daza ML, Cuellar-Saenz Y, Nualart F, Ondo-Mendez A, Del Riesgo L, Castillo-Rivera F, Garzón R.

J Cell Biochem. 2017 Jul;118(7):1868-1878. doi: 10.1002/jcb.25890. Epub 2017 Mar 28.

PMID:
28106284
26.

Long noncoding RNAs to predict survival in acute myeloid leukemia: a step toward personalized medicine?

Bhatnagar B, Garzon R.

Biomark Med. 2016 Sep;10(9):935-8. doi: 10.2217/bmm-2016-0173. Epub 2016 Aug 22. No abstract available.

PMID:
27548737
27.

miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency.

Lu Y, Hippen KL, Lemire AL, Gu J, Wang W, Ni X, Ranganathan P, Levine BL, Riley JL, June CH, Turka LA, Munn DH, Garzon R, Lu L, Blazar BR.

Blood. 2016 Sep 8;128(10):1424-35. doi: 10.1182/blood-2016-05-714535. Epub 2016 Aug 2.

28.

Germinated, toasted and cooked chickpea as ingredients for breadmaking.

Ouazib M, Garzon R, Zaidi F, Rosell CM.

J Food Sci Technol. 2016 Jun;53(6):2664-72. doi: 10.1007/s13197-016-2238-4. Epub 2016 Jun 1.

29.

MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment.

Leoncini PP, Bertaina A, Papaioannou D, Flotho C, Masetti R, Bresolin S, Menna G, Santoro N, Zecca M, Basso G, Nigita G, Veneziano D, Pagotto S, D'Ovidio K, Rota R, Dorrance A, Croce CM, Niemeyer C, Locatelli F, Garzon R.

Oncotarget. 2016 Aug 23;7(34):55395-55408. doi: 10.18632/oncotarget.10577.

30.

XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.

Ranganathan P, Kashyap T, Yu X, Meng X, Lai TH, McNeil B, Bhatnagar B, Shacham S, Kauffman M, Dorrance AM, Blum W, Sampath D, Landesman Y, Garzon R.

Clin Cancer Res. 2016 Dec 15;22(24):6142-6152. Epub 2016 Jun 29.

31.

Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia.

Maharry SE, Walker CJ, Liyanarachchi S, Mehta S, Patel M, Bainazar MA, Huang X, Lankenau MA, Hoag KW, Ranganathan P, Garzon R, Blachly JS, Guttridge DC, Bloomfield CD, de la Chapelle A, Eisfeld AK.

Cancer Discov. 2016 Sep;6(9):1036-51. doi: 10.1158/2159-8290.CD-16-0023. Epub 2016 Jun 27.

32.

Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.

Hing ZA, Fung HY, Ranganathan P, Mitchell S, El-Gamal D, Woyach JA, Williams K, Goettl VM, Smith J, Yu X, Meng X, Sun Q, Cagatay T, Lehman AM, Lucas DM, Baloglu E, Shacham S, Kauffman MG, Byrd JC, Chook YM, Garzon R, Lapalombella R.

Leukemia. 2016 Dec;30(12):2364-2372. doi: 10.1038/leu.2016.136. Epub 2016 May 20.

33.

Acute Myeloid Leukemia: A Concise Review.

Saultz JN, Garzon R.

J Clin Med. 2016 Mar 5;5(3). pii: E33. doi: 10.3390/jcm5030033. Review.

34.

Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents.

Cheng H, Xie Z, Jones WP, Wei XT, Liu Z, Wang D, Kulp SK, Wang J, Coss CC, Chen CS, Marcucci G, Garzon R, Covey JM, Phelps MA, Chan KK.

AAPS J. 2016 May;18(3):737-45. doi: 10.1208/s12248-016-9876-3. Epub 2016 Mar 4.

35.

HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.

Lai TH, Ewald B, Zecevic A, Liu C, Sulda M, Papaioannou D, Garzon R, Blachly JS, Plunkett W, Sampath D.

Clin Cancer Res. 2016 Jul 15;22(14):3537-49. doi: 10.1158/1078-0432.CCR-15-1063. Epub 2016 Feb 8.

36.

Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.

Walker AR, Wang H, Walsh K, Bhatnagar B, Vasu S, Garzon R, Canning R, Geyer S, Wu YZ, Devine SM, Klisovic R, Blum W, Marcucci G.

Leuk Lymphoma. 2016 Sep;57(9):2100-8. doi: 10.3109/10428194.2015.1135435. Epub 2016 Jan 19.

37.

The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.

Tarighat SS, Santhanam R, Frankhouser D, Radomska HS, Lai H, Anghelina M, Wang H, Huang X, Alinari L, Walker A, Caligiuri MA, Croce CM, Li L, Garzon R, Li C, Baiocchi RA, Marcucci G.

Leukemia. 2016 Apr;30(4):789-99. doi: 10.1038/leu.2015.308. Epub 2015 Nov 5.

PMID:
26536822
38.

Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).

Efebera YA, Geyer S, Andritsos L, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O'Donnell L, Daneault B, Bradbury H, Zhang J, Chen X, Garman S, Ranganathan P, Yu X, Hofstetter J, Yu J, Garzon R, Scrape SR, Lozanski G, Devine SM.

Biol Blood Marrow Transplant. 2016 Jan;22(1):71-9. doi: 10.1016/j.bbmt.2015.07.034. Epub 2015 Aug 6.

39.

Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia.

Dorrance AM, Neviani P, Ferenchak GJ, Huang X, Nicolet D, Maharry KS, Ozer HG, Hoellarbauer P, Khalife J, Hill EB, Yadav M, Bolon BN, Lee RJ, Lee LJ, Croce CM, Garzon R, Caligiuri MA, Bloomfield CD, Marcucci G.

Leukemia. 2015 Nov;29(11):2143-53. doi: 10.1038/leu.2015.139. Epub 2015 Jun 9.

40.

Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.

Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, Wang H, Wu YZ, Alachkar H, Anghelina M, Dorrance A, Curfman J, Bloomfield CD, Medeiros BC, Perrotti D, Lee LJ, Lee RJ, Caligiuri MA, Pichiorri F, Croce CM, Garzon R, Guzman ML, Mendler JH, Marcucci G.

Leukemia. 2015 Oct;29(10):1981-92. doi: 10.1038/leu.2015.106. Epub 2015 May 14.

41.

Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.

Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, Phelps MA, Devine S, Shacham S, Kauffman M, Marcucci G, Blum W, Garzon R.

Blood. 2015 Apr 23;125(17):2689-92. doi: 10.1182/blood-2014-10-607648. Epub 2015 Feb 25.

42.

Expression and prognostic impact of lncRNAs in acute myeloid leukemia.

Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrózek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, Eisfeld AK, Blachly JS, Blum W, Caligiuri MA, Stone RM, Marcucci G, Croce CM, Byrd JC, Bloomfield CD.

Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18679-84. doi: 10.1073/pnas.1422050112. Epub 2014 Dec 15.

43.

Embolization of splenorenal shunt associated to portal vein thrombosis and hepatic encephalopathy.

Franzoni Lde C, de Carvalho FC, Garzon RG, Yamashiro Fda S, Augusti L, Santos LA, Dorna Mde S, Baima JP, Lima TB, Caramori CA, Silva GF, Romeiro FG.

World J Gastroenterol. 2014 Nov 14;20(42):15910-5. doi: 10.3748/wjg.v20.i42.15910.

44.

A large scale expression study associates uc.283-plus lncRNA with pluripotent stem cells and human glioma.

Galasso M, Dama P, Previati M, Sandhu S, Palatini J, Coppola V, Warner S, Sana ME, Zanella R, Abujarour R, Desponts C, Teitell MA, Garzon R, Calin G, Croce CM, Volinia S.

Genome Med. 2014 Oct 2;6(10):76. doi: 10.1186/s13073-014-0076-4. eCollection 2014.

45.

Pluripotent stem cell miRNAs and metastasis in invasive breast cancer.

Volinia S, Nuovo G, Drusco A, Costinean S, Abujarour R, Desponts C, Garofalo M, Baffa R, Aeqilan R, Maharry K, Sana ME, Di Leva G, Gasparini P, Dama P, Marchesini J, Galasso M, Manfrini M, Zerbinati C, Corrà F, Wise T, Wojcik SE, Previati M, Pichiorri F, Zanesi N, Alder H, Palatini J, Huebner KF, Shapiro CL, Negrini M, Vecchione A, Rosenberg AL, Croce CM, Garzon R.

J Natl Cancer Inst. 2014 Oct 11;106(12). pii: dju324. doi: 10.1093/jnci/dju324. Print 2014 Dec. Erratum in: J Natl Cancer Inst. 2014 Nov:106(11):dju373doi:10.1093/jnci/dju373. Garzon, Maria Elena Sana Ramiro [Corrected to Garzon, Ramiro and Sana, Maria Elena].

46.

The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells.

Pinzón-Daza ML, Salaroglio IC, Kopecka J, Garzòn R, Couraud PO, Ghigo D, Riganti C.

J Cereb Blood Flow Metab. 2014 Aug;34(8):1258-69. doi: 10.1038/jcbfm.2014.100. Epub 2014 Jun 4.

47.

The use of molecular genetics to refine prognosis in acute myeloid leukemia.

Bhatnagar B, Garzon R.

Curr Hematol Malig Rep. 2014 Jun;9(2):148-57. Review.

PMID:
24659319
48.

The (miR)e of CTCL.

Mishra A, Garzon R.

Blood. 2014 Mar 6;123(10):1438. doi: 10.1182/blood-2014-01-548578.

49.

Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML.

Havelange V, Ranganathan P, Geyer S, Nicolet D, Huang X, Yu X, Volinia S, Kornblau SM, Andreeff M, Croce CM, Marcucci G, Bloomfield CD, Garzon R.

Blood. 2014 Apr 10;123(15):2412-5. doi: 10.1182/blood-2013-10-532374. Epub 2014 Mar 4.

50.

SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.

Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrózek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Garzon R, Bloomfield CD, Marcucci G.

J Clin Invest. 2014 Apr;124(4):1512-24. doi: 10.1172/JCI70921. Epub 2014 Mar 3.

Supplemental Content

Loading ...
Support Center